Table 1. Characteristics of the individuals included in the analysis according to their vaccination status, Navarre, Spain, January–April 2021 (n = 20,961).

Characteristics	Total		Vaccinated		Comirnaty vaccine				Vaxzevria vaccine		Moderna vaccine
	Total		Any dose		1 dose		2 doses		1 dose		1 dose	2 doses
	Number	%	Number	%	Number	%	Number	%	Number	%	Number	Number
Age groups (years)
18–39	8,008	38.2	377	27.3	27	8.7	124	25.3	217	41.4	4	5
40–59	8,414	40.1	487	35.3	57	18.4	212	43.2	203	38.7	4	11
≥ 60	4,539	21.7	517	37.4	226	72.9	155	31.6	104	19.8	27	5
Sex
Male	10,302	49.1	367	26.6	93	30.0	82	16.7	176	33.6	13	3
Female	10,659	50.9	1014	73.4	217	70.0	409	83.3	348	66.4	22	18
Major chronic conditions
No	14,883	71.0	889	64.4	141	45.5	313	63.7	406	77.5	14	15
Yes	6,078	29.0	492	35.6	169	54.5	178	36.3	118	22.5	21	6
Contact setting
Household	10,574	50.4	649	47.0	141	45.5	246	50.1	231	44.1	18	13
Other	10,387	49.6	732	53.0	169	54.5	245	49.9	293	55.9	17	8
Month
January	6,842	32.6	28	2.0	27	8.7	0	0.0	0	0.0	1	0
February	2,956	14.1	82	5.9	48	15.5	24	4.9	6	1.1	4	0
March	4,331	20.7	347	25.1	82	26.5	120	24.4	128	24.4	10	7
April	6,832	32.6	924	66.9	153	49.4	347	70.7	390	74.4	20	14
SARS-CoV-2 infection outcomes
All infections	7,240	34.5	260	18.8	90	29.0	61	12.4	99	18.9	9	1
Symptomatic COVID-19	5,467	26.1	161	11.7	62	20.0	25	5.1	67	12.8	6	1
COVID-19 hospitalisation	559	2.7	11	0.8	7	2.3	1	0.2	1	0.2	2	0
Total	20,961	100	1,381	100	310	100	491	100	524	100	35	21

COVID-19: coronavirus disease; SARS-CoV-2: severe acute respiratory syndrome coronavirus 2.

Comparison of brands should be avoided from this study since they were not randomly distributed.